On Tuesday, RAPT Therapeutics Inc (NASDAQ: RAPT) was 3.63% up from the session before settling in for the closing price of $1.93. A 52-week range for RAPT has been $1.64 – $27.35.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -36.87%. When this article was written, the company’s average yearly earnings per share was at 19.19%. With a float of $31.00 million, this company’s outstanding shares have now reached $34.40 million.
The extent of productivity of a business whose workforce counts for 131 workers is very important to gauge. In terms of profitability, gross margin is 65.02%, operating margin of -2439.18%, and the pretax margin is -2277.44%.
RAPT Therapeutics Inc (RAPT) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward RAPT Therapeutics Inc stocks. The insider ownership of RAPT Therapeutics Inc is 11.19%, while institutional ownership is 82.24%. The most recent insider transaction that took place on Jan 05 ’24, was worth 20,456. In this transaction CHIEF SCIENTIFIC OFFICER of this company sold 898 shares at a rate of $22.78, taking the stock ownership to the 27,820 shares. Before that another transaction happened on Dec 21 ’23, when Company’s Chief Medical Officer sold 2,500 for $21.68, making the entire transaction worth $54,200. This insider now owns 15,020 shares in total.
RAPT Therapeutics Inc (RAPT) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.82 earnings per share (EPS) during the time that was less than consensus figure (set at -0.75) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.19% per share during the next fiscal year.
RAPT Therapeutics Inc (NASDAQ: RAPT) Trading Performance Indicators
You can see what RAPT Therapeutics Inc (RAPT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.12, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.89 in one year’s time.
Technical Analysis of RAPT Therapeutics Inc (RAPT)
The latest stats from [RAPT Therapeutics Inc, RAPT] show that its last 5-days average volume of 0.25 million was inferior to 0.72 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 76.23%. Additionally, its Average True Range was 0.18.
During the past 100 days, RAPT Therapeutics Inc’s (RAPT) raw stochastic average was set at 15.19%, which indicates a significant decrease from 62.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.16% in the past 14 days, which was higher than the 85.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9600, while its 200-day Moving Average is $7.0400. Now, the first resistance to watch is $2.1800. This is followed by the second major resistance level at $2.3500. The third major resistance level sits at $2.4900. If the price goes on to break the first support level at $1.8700, it is likely to go to the next support level at $1.7300. The third support level lies at $1.5600 if the price breaches the second support level.
RAPT Therapeutics Inc (NASDAQ: RAPT) Key Stats
There are 34,903K outstanding shares of the company, which has a market capitalization of 69.80 million. As of now, sales total 0 K while income totals -116,800 K. Its latest quarter income was 0 K while its last quarter net income were -27,660 K.
